Merging tumor targeting and molecular-genetic imaging into an integrated platform is limited by lack of strategies to enable systemic yet liganddirected delivery and imaging of specific transgenes. Many eukaryotic viruses serve for transgene delivery but require elimination of native tropism for mammalian cells; in contrast, prokaryotic viruses can be adapted to bind to mammalian receptors but are otherwise poor vehicles. Here we introduce a system containing cis-elements from adeno-associated virus (AAV) and single-stranded bacteriophage. Our AAV/phage (AAVP) prototype targets an integrin. We show that AAVP provides superior tumor transduction over phage and that incorporation of inverted terminal repeats is associated with improved fate of the delivered transgene. Moreover, we show that the temporal dynamics and spatial heterogeneity of gene expression mediated by targeted AAVP can be monitored by positron emission tomography. This new class of targeted hybrid viral particles will enable a wide range of applications in biology and medicine.
INTRODUCTION
Integration of tumor targeting and imaging technologies into a single discipline has the potential to improve the practice of medicine. Noninvasive molecular-genetic imaging of temporal dynamics and spatial heterogeneity of transgene expression can provide the means for the assessment of specificity of targeting and for monitoring the efficacy of genetic transfer Gross and Piwnica-Worms, 2005a; Medintz et al., 2005; Tai and Laforest, 2005) . However, this emerging field depends on development of ligand-directed particles to enable systemic targeted delivery and molecular imaging of reporter trangenes.
Currently, eukaryotic viruses unquestionably provide superior transgene delivery and transduction (Kootstra and Verma, 2003) , but ligand-directed targeting of such vectors requires ablation of their native tropism for mammalian cell-membrane receptors (Mü ller et al., 2003; Mizuguchi and Hayakawa, 2004) . In contrast, prokaryotic viruses such as bacteriophage (phage) are considered poor vehicles for mammalian cell transduction. However, despite their inherent shortcomings as ''eukaryotic'' viruses, phage particles have no tropism for mammalian cells (Barrow and Soothill, 1997; Barbas et al., 2001 ) and have even been adapted to transduce such cells (Ivanenkov et al., 1999; Larocca et al., 1999; Poul and Marks, 1999; Piersanti et al., 2004) , albeit at low efficiency. Phage display-based technology allows direct ligand-directed selection of homing peptides to corresponding receptors selectively expressed in normal or tumor tissues (Hajitou et al., 2006) . We hypothesized that combining the favorable biological attributes of eukaryotic viruses to those of prokaryotic viruses might yield chimeric particles with potential as targeted delivery tools for molecular imaging. Since the genomes of recombinant adeno-associated virus (AAV) and single-stranded phage consist of compatible DNA, we generated novel chimeras between AAV and fd-tet (Zacher et al., 1980) , an M13-derived filamentous phage, displaying short peptides (Smith and Scott, 1993) and evaluated them for tumor targeting and molecular imaging of Herpes simplex virus thymidine kinase (HSVtk) gene expression with [
18 F]FEAU and positron emission tomography (PET) in preclinical tumor models.
RESULTS AND DISCUSSION

Ligand-Directed Particles Are Functional in Mammalian Cells
As a proof of concept, we constructed a targeted chimeric virus comprised of recombinant AAV and an fd-tet phage clone displaying the double-cyclic peptide CDCRGDCFC (termed RGD-4C) phage (Pasqualini et al., 1997; Arap et al., 1998; Ellerby et al., 1999) . The RGD-4C peptide binds to av integrins, a cell-surface receptor overexpressed in both tumor and endothelial cells (Arap et al., 1998; Hood et al., 2002) . To obtain chimeric viruses (hereafter referred to as AAV/phage; AAVP), we inserted an eukaryotic gene cassette from AAV in an intergenomic region of RGD-4C phage (RGD-4C AAVP); insertless phage (nontargeted AAVP); or phage displaying control peptides, such as scrambled RGD-4C AAVP or D/E mutant (termed RGE-4C) AAVP, and packaged it with the phage DNA into the phage capsid (see Figure S1 in the Supplemental Data available with this article online). In order to show that the cis-elements of the resulting targeted chimeric virus remain functional, we evaluated the ligand properties of the RGD-4C peptide and the rescuing properties of the inverted terminal repeats (ITRs) in the context of AAVP. First, to evaluate peptide specificity, we show that RGD-4C AAVP binds to mammalian cells expressing av integrins, in contrast to the nontargeted AAVP or AAVP displaying negative control peptides such as RGE-4C or various scrambled versions of the RGD-4C sequence ( Figure 1A ), which neither bind to nor infect mammalian cells. We also demonstrate that RGD-4C AAVP carrying reporter genes can mediate ligand-directed internalization ( Figure 1B ) and transduction of mammalian cells (Figure 1C) relative to controls. For cell internalization experiments, negative controls included nontargeted AAVP, various scrambled RGD-4C AAVP, or RGE-4C AAVP (Figure 1B) ; for cell transduction experiments, nontargeted AAVP ( Figure 1C ), scrambled RGD-4C AAVP, or RGE-4C AAVP (data not shown) served as negative controls. Consistent with these results, we have previously demonstrated that the synthetic RGD-4C peptide specifically inhibits cell binding and internalization of various targeted RGD-4C phage-based constructs (Giordano et al., 2001; Chen et al., 2004; unpublished data) . Finally, we show that mammalian cell transduction can also be specifically competed by the synthetic RGD-4C peptide relative to negative controls such as nontargeted AAVP ( Figure 1D ), scrambled RGD-4C, or RGE-4C (data not shown). To rule out the possibility that some of these results (Figures 1A and 1B) could represent an artifact resulting from selective failure of the glycine (low pH) wash step to remove AAVP from cell membranes, we performed ice-cold control experiments (Giordano et al., 2001) , in which we observed cell binding but not internalization mediated by RGD-4C AAVP (data not shown), thus supporting our interpretation.
Next, to evaluate whether the ITRs are still functional in the AAVP particle, we performed rescue experiments. We show that functional recombinant AAV particles are generated from mammalian cells transduced with the RGD-4C AAVP only but not from the cells transduced with negative control constructs ( Figure 1E ). These data establish that the genetic chimerization resulting in an RGD-4C AAVP particle does not fundamentally alter (1) the peptide targeting properties of the ligand-directed RGD-4C phage or (2) the ability to rescue recombinant AAV particles from mammalian cells transduced by RGD-4C AAVP. A side-by-side time course of a reporter transgene expression revealed that RGD-4C AAVP transduction was detectable for much longer compared to that of the RGD-4C phage (Table S1 ).
Molecular Mechanisms of Transgene Expression
To gain an insight into the molecular mechanisms of transgene expression mediated by AAVP, we investigated the fate of the transduced genome in mammalian cells. First, we generated stably transduced cell lines by using GFPneo-expressing AAVP to allow for the selection of individual transduced cell clones. Either RGD-4C AAVPGFPneo or RGD-4C phage-GFPneo lacking AAV ITRs were used to transduce av integrin-expressing 293 cells, and clones were isolated under G418 selection. Rescue experiments showed functional recombinant AAVGFPneo generated from all of the RGD-4C AAVP-GFPneo 293 cell clones, but none generated from the RGD-4C phage-GFPneo clones (data not shown), thus confirming that the chimeric individual clones contain functional ITRs. Although cells transduced with the nonchimeric RGD-4C phage-GFPneo retained G418 resistance, GFP expression was generally weaker than that of the RGD-4C AAVP-GFPneo clones ( Figure 2A ). We then set out to determine the fate of the GFPneo transgene cassette in stably transduced clones by a comprehensive restriction-enzyme digestion of genomic DNA followed by Southern blotting and PCR analysis (Figure 2 ; Figure S2 and Table S2 ). To prove persistence of the transgene cassette, genomic DNA was digested with AflII and XhoI to detect the release of full-length transgene cassettes prior to the analysis. We observed such release in 100% of the clones transduced by RGD-4C AAVP (n = 9 of 9 clones), compared to only in 33% of the clones (n = 3 of 9 clones) transduced by the nonchimeric RGD-4C phage construct ( Figure 2B ). We next designed another restriction digest of genomic DNA to detect potential concatemeric forms of the transgene cassette (Lieber et al., 1999; Hsiao et al., 2001) . We detected the presence of head-to-tail concatemers of the transgene cassette in 67% of the clones transduced by RGD-4C AAVP (n = 6 of 9 clones), while no such concatemers were detected in clones transduced by the nonchimeric RGD-4C phage construct ( Figure 2C ). To identify possible additional concatemeric forms of the transgene cassette, we performed a multiplex PCR by using primers flanking the 5 0 and 3 0 ends of the constructs. Again, we found no concatemers in clones transduced by nonchimeric RGD-4C phage construct, whereas 100% of clones transduced by RGD-4C AAVP contained concatemeric forms (n = 9 of 9 clones), all of them found in headto-tail orientation ( Figure S2B ). Moreover, topo cloning of smaller PCR products revealed the head-to-tail orientation of the transgene cassette with ITR deletions (Figure S2C) (Yang et al., 1997) . Finally, although the large PCR products could not be sequenced, their sizes suggest the presence of concatemers with intact ITRs at the junction site. An individual analysis of DNA for each single clone is also detailed in Table S2 . These data suggest that AAVP may bestow an advantage in gene expression by means of an altered fate of the transgene cassette through maintenance of the entire mammalian transgene cassette, better persistence of episomal DNA, formation of concatemers of the transgene cassette, or perhaps a combination of these non-mutually exclusive mechanisms. These observations are consistent with recent developments in the understanding of AAV (McCarty et al., 2004) . Tumor Targeting In Vivo and Molecular-Genetic Imaging After demonstrating that the central elements of the targeted chimeric viral particle (i.e., the RGD-4C peptide and the AAV ITRs) are intact and functional and after elucidating the molecular mechanisms of AAVP-mediate gene expression in mammalian cells, we evaluated the specificity and efficacy of gene delivery into tumors after systemic administration of AAVP. As an initial preclinical model, we used nude mice bearing subcutaneous tumor xenografts derived from human Kaposi sarcoma KS1767 cells (Arap et al., 1998; Ellerby et al., 1999) . First, to verify that the viral construct targets to KS1767-derived xenografts in mice, we intravenously administered either RGD-4C AAVP or one of several negative controls (nontargeted AAVP, scrambled RGD-4C AAVP, or RGE-4C AAVP). After a 3-5 min circulation time, a strong anti-AAVP staining in tumor vasculature was observed in mice that received RGD-4C AAVP but not in control mice ( Figure 3A ). We next used an RGD-4C AAVP variant encoding the GFP gene as a reporter to determine, by using in situ immunofluorescence microscopic imaging, whether this vector (RGD-4C AAVP-GFP) could transduce KS1767-derived xenografts. We performed immunostaining against GFP in tumors and in different organs 7 days after systemic administration of either RGD-4C AAVP-GFP or negative control constructs into tumor-bearing mice. Immunofluorescence revealed GFP expression largely in tumor blood vessels and surrounding tumor cells in mice that received RGD-4C AAVP-GFP. In contrast, no GFP staining was detected in tumors from control mice that received nontargeted, scrambled, or mutant AAVP-GFP ( Figure 3B ). This staining pattern suggests that ligand-directed transduction is mediated by targeting of av integrins in the vascular endothelium of tumors. Consistently, several nontarget control organs (brain, liver, pancreas, and kidney) lacked tissue expression of GFP ( Figure S3 ). These results indicate that RGD-4C AAVP particles can specifically target tumor xenografts by a liganddirected mechanism and transduce them after systemic administration in vivo. Next, we assessed the efficacy of preclinical bioluminescence imaging (BLI) and clinically applicable molecular-genetic PET imaging with [
18 F]FEAU for noninvasive monitoring of temporal dynamics and spatial heterogeneity of the firefly luciferase (Luc) and the HSVtk reportergene expression, respectively, in living tumor-bearing mice following systemic administration of the RGD-4C AAVP. These molecular-genetic imaging studies were conducted in a preclinical model of human prostate cancer since this particularly prevalent tumor remains a challenge to properly image in patients. We first used a standard experimental setup for in vivo imaging of the Luc transgene reporters in tumor-bearing mice ( Figure 4A ). We selected BLI of Luc expression because it is a very sensitive method for reporter-gene imaging in mice and has virtually no nonspecific background activity in the images (Gross and Piwnica-Worms, 2005a; Gelovani Tjuvajev and Blasberg, 2003) . Tumor-specific expression of Luc was observed in DU145 tumors in mice receiving RGD-4C AAVP-Luc. In contrast, tumor-associated bioluminescence signals could not be observed in control mice receiving the nontargeted AAVP-Luc or scrambled RGD-4C AAVP-Luc. No bioluminescence was observed in normal organs with any AAVP tested. These data confirm the tumor specificity of RGD-4C AAVP-mediated targeting and transgene expression observed with immunofluorescence microscopy imaging studies with RGD-4C AAVP-GFP. Consistent with previous results presented here ( Figure S3 ), the kinetics of distribution suggests that, despite the nonspecific hepatic clearance of phage particles (Geier et al., 1973) , such a phenomenon does not result in an undesirable gene transduction of the liver. These observations are in sharp contrast with the welldocumented nonspecific transduction of normal organs (such as liver) by the mammalian viral gene delivery vectors. By using BLI in vivo, Luc reporter-transgene expression within tumors was clearly detectable at day 3 after AAVP administration and increased gradually to reach maximal levels by day 10. Repetitive two-dimensional BLI of Luc reporter-gene expression was performed every other day and provided an initial cost-effective strategy to study the specificity, temporal dynamics, and spatial heterogeneity of reporter-transgene expression mediated by AAVP.
However . Previous studies established that PET imaging of HSVtk expression provides the ability to define the location, magnitude, and duration of transgene expression (Tjuvajev et al., 1998 (Tjuvajev et al., , 1999 Ray et al., 2001 ; Massoud and Gambhir, We generated 293 stable clonal cell lines (n = 9 per each group) that were then analyzed. Individual clones were termed AAVP 1-9 or phage 1-9. Nontransduced 293 parental cells served as a negative control. 2003). It has also been previously determined that the magnitude of accumulated radiolabeled tracers in HSVtktransduced cell lines and tumors in vivo correlates with the level of HSVtk expression Gross and Piwnica-Worms, 2005a; Tai and Laforest, 2005) . In the studies presented here, we selected, synthesized, and used the radiolabeled nucleoside analog
, which is a better radiolabeled substrate for the HSVtk enzyme than other nucleoside analogs, especially from pharmacokinetic considerations (a very low background activity in all normal organs and tissues) (Kang et al., 2005) . By using repetitive PET imaging with [ 18 F]FEAU (on days 0, 3, 5, 10, and 16), we have visualized and quantitated the temporal dynamics and spatial heterogeneity of HSVtk gene expression after a single systemic administration of RGD-4C AAVP-HSVtk or nontargeted AAVP-HSVtk in DU145-derived tumor xenografts and other organs and tissues in nude mice ( Figure 4B ). Tumor xenograft sizes ($150 mm 3 ) before, as well as tumor growth rates after, administration of either RGD4C AAVPHSVtk or nontargeted AAVP-HSVtk were similar in both cohorts of mice ( Figure 4C ). PET imaging with [
18 F]FEAU revealed a gradual increase in the level of HSVtk transgene expression in tumors (increase in % administered intravenous dose per gram) during the initial 5 days after administration of RGD-4C AAVP-HSVtk, followed by gradual stabilization of HSVtk expression levels toward day 10 post vector administration. In contrast, in control tumorbearing mice receiving nontargeted AAVP-HSVtk, only a minor increase in tumor accumulation of [ 18 F]FEAU was observed at day 3, which rapidly decreased to background level ( Figure 4D ). Consistent with preceding BLI experiments, no [ 18 F]FEAU PET-detectable HSVtk expression was observed in nontarget organs or tissues ( Figure 4B ). Indeed, low-level heterogeneous activity in the PET images (blue color) represents normal background activity, which was intentionally intensified in the images presented to demonstrate that no truncation of low levels of radioactivity was made to artificially ''improve'' the specificity of HSVtk expression in tumors versus nontarget tissues. When tumors grew to reliably palpable sizes ($350-400 mm 3 ) and a plateau of HSVtk expression was achieved in tumors, treatment with GCV was initiated in all cohorts of animals ( Figure 4C ). PET imaging with [
18 F]fluorodeoxyglucose ([ 18 F]FDG) served to monitor glucose metabolism and GCV-induced changes in tumor viability. Two days before initiation of GCV therapy (day 9 post vector administration), the DU145 tumors in both groups of mice were viable and actively accumulated [
18 F]FDG ( Figure 4E ). After GCV therapy, the volume of tumors in mice that received RGD-4C AAVP-HSVtk was significantly smaller than in mice that received nontargeted AAVP-HSVtk (p < 0.05; Figure 4C ). Moreover, tumor xenografts were also metabolically suppressed, as evidenced by a decrease in accumulation of [ 18 F]FDG (Figure 4E ). The levels of HSVtk expression in tumors of mice administered with RGD-4C AAVP-HSVtk were also significantly decreased after GCV therapy, as evidenced by a sharp decrease in [ 18 F]FEAU accumulation in PET images ( Figure 4D ), which were obtained 24 hr after the last GCV dose (to avoid competition with FEAU). These studies confirm the specificity of tumor targeting by RGD-4C AAVP and demonstrate that the level of HSVtk transgene expression is adequately high for effective prodrug activation of GCV.
In order to evaluate efficacy horizontally in other preclinical models, we assembled a panel of tumor cell lines from different species and histological origins and generated tumors in immunosuppressed or immunocompetent mice. Cohorts of Kaposi sarcoma (KS1767) derived tumor-bearing mice systemically received a single intravenous dose of either the RGD-4C AAVP-HSVtk or nontargeted AAVP-HSVtk (control), followed by GCV treatment in all groups. Marked tumor growth suppression was observed in tumor-bearing mice receiving RGD-4C AAVPHSVtk as compared to mice treated with vehicle or mice that received nontargeted AAVP ( Figure 5A ). Similar tumor growth-suppressive effects were observed in UC3-derived bladder carcinomas ( Figure 5B ) and DU145-derived prostate carcinomas ( Figure 5C ) in nude mice, even if larger tumor xenografts were treated ( Figure 5D ) and consistent with the imaging results presented (Figure 4) .
To rule out the possibility that the observed antitumor effects were either species specific or xenograft specific, we sought to analyze the efficacy of the RGD-4C AAVPHSVtk on a standard mouse tumor model. We chose an isogenic tumor in which EF43-FGF4 mouse mammary cells are administered subcutaneously to induce rapid growth of highly vascularized tumors in immunocompetent mice (Hajitou et al., 2001 ). First, we established the ligand-directed homing of RGD-4C AAVP to EF43-FGF4-derived tumors by anti-phage immunostaining ( Figure S4 ). Either RGD-4C AAVP-GFP or nontargeted AAVP-GFP was administered intravenously to mice bearing isogenic mammary tumors for a 3-5 min circulation time. Unlike the nontargeted AAVP-GFP, RGD-4C AAVP-GFP produced a strong anti-phage staining in tumors ( Figure S4A ). Next, we performed immunofluorescence with an anti-GFP antibody at 7 days after intravenous administration to reveal strong GFP expression in the tumors in mice that received RGD-4C AAVP-GFP; in contrast, no GFP staining was detected in tumors from mice that received nontargeted AAVP-GFP; consistently, an anti-av integrin antibody detected strong expression in EF43-FGF4 tumors ( Figure S4B ). Again, a single systemic dose of RGD-4C AAVP-HSVtk followed by GCV markedly inhibited the growth of EF43-FGF-4 tumors (Figures 5E-5G and Figure 6 ). Moreover, when tumors grew back after termination of therapy, repeated administrations of RGD-4C AAVP-HSVtk again inhibited EF43-FGF4 tumor growth and improved survival of tumor-bearing mice ( Figure 5F ). Phage-based particles are known to be immunogenic, but this feature can be modulated through targeting itself (Trepel et al., 2001) . In fact, RGD-4C AAVP-HSVtk plus GCV remained surprisingly effective on phage-vaccinated immunocompetent mice despite very high titers of circulating anti-phage IgG ( Figure 5G ). In selective experiments, a comprehensive panel of negative experimental controls including vehicle alone, vehicle plus GCV, nontargeted AAVP, nontargeted AAVP plus GCV, targeted RGD-4C AAVP, targeted RGD-4C AAVP-GFP, and targeted RGD-4C AAVP-GFP plus GCV (mock transduction) were used ( Figure 6A and data not shown).
To check for posttreatment effects, we obtained detailed histopathological analysis of EF43-FGF4 tumors recovered 7 days after therapy. We noted extensive tumor destruction caused by the single systemic dose of RGD-4C AAVP-HSVtk plus GCV. Specifically, hematoxylin and eosin (H&E) staining revealed uniform destruction of the central area of the tumor and only a small viable outer rim; in contrast, nontargeted AAVP-HSVtk had no such effect ( Figure 6B) . Staining with an anti-CD31 antibody confirmed both disrupted tumor blood vessels within the tumor central region and preserved vasculature toward the outer rim, whereas no damage was observed in the tumors treated with nontargeted AAVP-HSVtk ( Figure 6B ). We also evaluated the tumors for terminal deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining, which marks apoptotic cells, because the HSVtk/GCV strategy is associated with apoptotic death of cells. In tumors treated with RGD-4C AAVP-HSVtk and GCV, TUNEL staining detected apoptosis in the tumor central region but not within the outer rim, while no apoptosis was observed in tumors from mice that received nontargeted AAVP-HSVtk chimera ( Figure 6B ). Control organs removed from tumor-bearing mice treated by the same experimental protocol revealed no histopathologic abnormalities ( Figure S5 ). Together, these results show that a single systemic dose of RGD-4C AAVP-HSVtk plus GCV maintenance can suppress tumor growth. Some of our results merit further discussion. First, the relative contribution of targeting each tumor compartment (i.e., tumor cells versus tumor vascular endothelium and/ or stroma) will depend on the ligand-receptor system and on the experimental model (or models) used. For instance, the expression of the membrane target (i.e., av integrins) in tumor cells will vary from low (EF43-FGF4) to strong (KS1767). Moreover, aside from the specific optimal dose for transduction of each model (and application) used, there is also an optimal time to examine transgene expression. In other words, the stoichiometry of reporter-gene expression depends not only on levels and patterns of reporter expression in individual cells but also on the relative number of proliferating transgeneexpressing cells versus dying transgene-expressing cells. Thus, while we used fixed parameters for the experiments presented here, further determination of targeted AAVP optimal doses and timeframes on a case-by-case basis still apply. Future translational studies will need to be conducted to determine what doses are clinically meaningful and how an AAVP-based system can be optimized for therapy of patients by using clinically applicable molecular-genetic imaging with PET.
Finally, one might speculate that a broad range of currently intractable biological questions well beyond molecular oncology will be addressed by using targeted AAVP, especially in combination with different preclinical and clinical molecular-genetic imaging settings. For example, the systemic ligand-directed delivery of constructs with tissue-and/or disease-specific promoters (instead of a CMV promoter) to target sites will allow monitoring expression of their corresponding native genes in vivo; such promoter-driven transcription of reporter activity will allow the study of cell trafficking and engraftment. Several noninvasive imaging applications such as experimental monitoring of substrate-specific degradation, protein-protein interactions, and other molecular events via reporter transactivation, complementation, or reconstitution strategies in cells and in whole animals (Luker et al., 2004; De and Gambhir, 2005; Gross and Piwnica-Worms 2005b) will likely follow. In fact, we have recently described networks of gold nanoparticles and bacteriophage as biological sensors and cell targeting agents (Souza et al., 2006) ; such technology can be combined with ligand-directed AAVP to further improve moleculargenetic imaging. On another note, AAVP itself may provide suitable reagents to study the mechanistic role of ITR structures in transgene persistence and chromosomal integration since (in contrast to AAV vectors) phage-based constructs with no ITRs can serve as negative experimental controls. In translational terms, the results presented here bode well with an existing framework leading to direct AAVP-based random peptide library screening in patients (Arap et al., 2002; Pentz et al., 2005) and may form the basis for the discovery of new or unrecognized human ligand receptors. Thus, many other systemic targeting and imaging applications in tandem will become possible in a relatively short time frame.
Conclusions
Ligand-directed AAVP combines desirable properties from two unrelated genetic systems to yield a targeted particle for molecular imaging. Attractive features include a cheap and high yield of production in host bacteria and no requirements for helper viruses or trans-acting factors. Moreover, the native tropism of AAV for mammalian cells is eliminated since there is no AAV capsid formation and the displayed ligand peptides allow homing to tissuespecific receptors. In the prototype presented here, the ligand-directed AAVP sustains no loss of systemic phage targeting properties and even acquires some posttargeting patterns associated with AAV. We have previously proposed that molecular imaging of marker genes would have the potential to assess therapeutic levels of expression and markedly improve our ability to predict response to therapies in which target genes are known. The introduction of ligand-directed AAVP for systemic targeting and molecular-genetic imaging, rationally designed along the lines described here, is a major step in that direction. Finally, one might speculate that (1) in addition to liganddirected targeting, further platform refinements such as transcriptional targeting will certainly be possible by incorporation of specific promoters and (2) other hybrid viruses containing prokaryotic and eukaryotic elements (such as, for instance, chimeras between adenovirus and doublestranded lambda phage) may also be envisioned for systemically targeted imaging of reporters. Based on this comprehensive analysis, it seems that the translation of our prototype particle may lead to realistic imaging of gene expression in cancer patients. In a larger context, given the favorable tissue-targeting and molecular-imaging profiles, ligand-directed AAVP is likely to be a useful tool in dissecting other relevant biological questions.
EXPERIMENTAL PROCEDURES
Design, Construction, and Generation of Targeted AAVP Particles RGD-4C phage and RGD-4C AAVP were engineered in a two-step process: generation of an intermediate (RGD-4C fUSE5-MCS) and subsequent production of RGD-4C phage construct and RGD-4C AAVP. RGD-4C fUSE5-MCS contained the oligonucleotide insert encoding the specific targeting peptide RGD-4C and a fragment of the fMCS plasmid that had a multicloning site (MCS) for insertion of the eukaryotic expression cassette. RGD-4C phage-derived fUSE5 DNA and phage-derived fMCS DNA were purified from lysates of E. coli (MC1061). We obtained the intermediate RGD-4C fUSE5-MCS by ligating a 5.4 kb BamHI/SacII fragment of the RGD-4C FUSE5 plasmid to the 4.1 kb BamHI/SacII fragment of the fMCS plasmid. Next, we created a targeted AAVP-GFP by cloning the PacI fragment (2.8 kb) of pAAV-eGFP plasmid (enhanced GFP; Stratagene) from ITR to ITR into the PstI site of RGD-4C fUSE5-MSC. Briefly, pAAV was digested with PacI to release a 2.8 kb fragment, which was blunted with DNA polymerase and cloned into the blunted PstI site of RGD-4C fUSE5-MSC. To generate the targeted phage constructs without ITRs, a 2.3 kb fragment located between the ITRs of pAAV-eGFP and containing pCMV-GFP and SV40 poly A was released by EcoRI digestion, blunted, and cloned into the MCS of RGD-4C fUSE5-MSC. To select cells expressing GFP, the BamHI-SacI fragment of the pQBI phosphoglycerate kinase-1 (QBIOgene) promoter containing a GFPneo fusion sequence was cloned in the NotI site of AAVP or control phage constructs to ensure that cells expressing GFP were G418-resistant. The GFPneo fragment of pQBI PGK was released by BamHI and SacI digestion and blunted with DNA polymerase; then, phosphorylated linkers to NotI were added. After NotI digestion, the 1.57 kb GFPneo fragment was cloned into the NotI site of AAVP or nonchimeric phage construct. Finally, to generate a targeted AAVP particle carrying the gene for HSVtk or Luc, the BamHI-NotI fragment containing HSVtk or Luc was subcloned into the BamHI-NotI site of pAAV plasmid to replace GFP. The ITR-HSVtk-ITR or ITR-Luc-ITR fragments were removed from pAAV-HSVtk and pAAV-Luc was then inserted into RGD-4C fUSE5-MCS. Constructs were verified by DNA sequencing and restriction analysis, purified from the culture supernatant of host E. coli (MC1061), resuspended in PBS, and recentrifuged. Resulting supernatants were titrated in E. coli (k91Kan). Serial dilutions were plated on Luria-Bertani (LB) agar plates containing tetracycline and kanamycin, and transducing units (TU) were determined by colony counting.
Mammalian Cell-Surface Binding and Internalization Assays
We used the biopanning and rapid analysis of selective interactive ligands (termed BRASIL) method (Giordano et al., 2001 ) to evaluate phage binding to intact cells. In brief, KS1767 cells were detached by EDTA and resuspended in Dulbecco's modified Eagle's medium (DMEM) containing 1% BSA at 4 Â 10 6 cells/ml. The cell suspension (50 ml) was incubated with 10 9 TU of either RGD-4C AAVP or AAVP clones displaying scrambled versions of RGD-4C (CDCFGDCRC, CDCGFDCRC, CRCDGFCDC), mutant RGE-4C peptide, or nontargeted control. After 2 hr, the AAVP/cell mixture (aqueous phase) was transferred to the top of a nonmiscible organic phase (200 ml solution in a 400 ml Eppendorf tube) consisting of dibutyl phthalate:cyclohexane (9:1 [v/v], D = 1.03 g/ml) and centrifuged at 10,000 Â g for 10 min at 4ºC. The tube was snap frozen in liquid nitrogen, the bottom of the tube was sliced off, the pellet was isolated, and membrane bound AAVP was recovered. For cell internalization, KS1767 cells were grown in tissue chamber slides, washed with PBS, incubated with 10 9 TU of RGD-4C AAVP or control AAVP displaying scrambled versions of RGD-4C or RGE-4C in DMEM containing 1% BSA at 37ºC, and washed with PBS to remove unbound AAVP after 4 hr incubation. Cell membrane bound clones were eluted by 20 mM glycine. Next, cells were washed three times with PBS, fixed with PBS containing 4% PFA at RT for 15 min, washed with PBS, permeabilized with 0.2% Triton X-100, washed with PBS, and blocked with PBS containing 1% BSA. Cells were then incubated with a 1:200 dilution of the primary anti-M13 phage antibody (Amersham) in PBS containing 1% BSA at RT for 2 hr, washed with PBS, and incubated with a 1:200 dilution of a Cy3-conjugated anti-rabbit secondary antibody in PBS containing 1% BSA for 1 hr at RT. Finally, cells were washed with PBS, fixed with PBS containing 4% PFA, mounted, and visualized in an optical fluorescence microscope.
Recombinant AAV Rescue Assay
Human 293 cells were infected with AAVP or phage. Four days after infection, cells were transfected with pXX2, an AAV rep-and capexpressing plasmid (Xiao et al., 1998) , and superinfected with adenovirus type 5. Cells were harvested 72 hr post adenoviral infection, and supernatants were used to infect new 293 cells. GFP expression was FACS analyzed 48 hr later.
Generation of Clonal Cell Lines
Human 293 cells were infected with RGD-4C AAVP-GFPneo or RGD-4C phage-GFPneo (at 10 6 TU per cell in each case). Single clones (n = 9
per group) were isolated under G418 selection and FACS analyzed for GFP expression at 12 weeks after selection. Stable clones were termed phage clones #1-9 for phage-GFPneo and AAVP clones #1-9 for AAVP-GFPneo.
Tumor Models
Tumor-bearing mice were established and tumor volumes were calculated as described (Hajitou et al., 2001; Arap et al., 2004; Marchiò et al., 2004 using a microPET R4 (Concorde Microsystems) equipped with a computer-controlled positioning bed. It has a 10.8 cm transaxial and 8 cm axial field of view (fov) without a septa and operates in a three-dimensional list mode. Fully three-dimensional list mode data were collected using an energy window of 350-750 kiloelectron volts and a time window of 6 ns. All raw data were first sorted into three-dimensional sinograms, followed by Fourier rebinning and OSEM image reconstruction using ASIPRO VM software (Concord Microsystems). Image pixel size was $1 mm transaxially with a 1.2 mm slice thickness. Radiolabeled [ 18 F]FEAU was synthesized to radiochemical purity greater than 99% by using 5-ethyluracil-2,5-bis-trimethylsilyl ether as the pyrimidine base for condensation with 1-bromo-2-deoxy-2-[ 18 F]fluoro-3,5-di-O-benzoyl-a-D-arabinofuranose (Alauddin et al., 2003 Immunohistochemistry Anesthetized mice were killed and perfused with PBS containing 4% PFA. Tumor vascularization was assessed on frozen sections by using a rat anti-mouse CD31 antibody (BD Biosciences). Apoptosis analysis was performed on paraffin-embedded sections with a TUNEL kit (Promega). For phage immunodetection, paraffin sections were incubated with a rabbit anti-phage antibody (Sigma) followed by a peroxidase-conjugated anti-rabbit secondary antibody (Dako). For GFP immunostaining, tissues were fixed for 2 hr in PBS containing 2% PFA and equilibrated for 48 hr in PBS containing 15% sucrose. Cryosections were postfixed in PBS containing 4% PFA for 20 min and blocked with 5% goat serum in PBS containing 1% BSA and 0.1% Triton X-100. Tissue sections were incubated with a rabbit affinity-purified GFP antibody (Molecular Probes) in 2% goat serum and 1% BSA. Sections were then stained with the secondary antibody AlexaFluor 488-conjugated goat anti-rabbit (Molecular Probes). av integrin immunostainings were performed on acetone-fixed frozen sections of tumors removed from PBS-perfused animals. Sections were incubated for 1 hr with a rat anti-integrin av monoclonal antibody (Chemicon), followed by a secondary Cy3-conjugated goat anti-rat antibody (Jackson ImmunoResearch).
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